Alligator Bioscience has been off to a hot start in 2023. First came the positive interim results from the phase II study in pancreatic cancer. Then, the first patient was dosed in a phase I study for. | May 4, 2023
Redeye comments on Alligator’s Q4 report. The key event during the quarter was mitazalimab showing strong results in the interim readout from OPTIMIZE-1, which derisks the clinical. | February 13, 2023